Genomic testing of your prostate cancer tumor analyzes the activity of genes that control the behavior of the tumor in your body to provide additional valuable information about your risk for disease recurrence.

The development of new and individualized ways to understand prostate cancer risk is important because we know that not all cancer is the same. Pathologic assessment of the tumor is valuable but doesn’t accurately predict the behavior of the tumor. And PSA doesn’t always allow doctors to accurately determine the extent of recurrence. As such, current clinical assessment tools may not tell the whole story.

The genomic fingerprint of metastatic prostate cancer is different from the genomic fingerprint of indolent, non-aggressive disease.

Genomic testing can help physicians and their patients make more informed decisions about management and treatment by arming them with more accurate, personalized information about the course of a patient’s disease. NCCN supports use of tumor-based molecular testing when determining risk for disease progression after surgery1.

Genomic tests such as Decipher® support treatment decisions by a) identifying who may safely avoid additional treatment, and b) determining who may benefit from earlier, more aggressive therapeutic options. This is the only test presently covered by Medicare for testing after surgery.

References
  1. NCCN. NCCN Clinical Guidelines in Oncology (NCCN Guideline). Prostate Cancer. Version 1. 2015. [cited 2014 October 24, 2014]; Available from: http://www.nccn.org/professionals/physician_
    gls/pdf/prostate.pdf.p. 3892-8.